7 results
The purpose of this investigation is: • To examine how the new drug BGG492 (study medication) will be absorbed, metabolized and excreted by the body in combination with the contraception pill which consists of ethinyl-estradiol and levonorgestrel…
* To examine how multiple oral doses of the test compound (an experimental medication) will be taken up by the body, metabolized and excreted by the body in combination with the oral contraception pill which consists of ethinyl-estradiol and…
The purpose of this study is to establish efficacy and safety of ligelizumab in adolescent and adult subjects with CSU who remain symptomatic despite standard of care treatment by demonstrating better efficacy over omalizumab.
The purpose of this study is to establish efficacy and safety of ligelizumab (QGE031) versus placebo in participants with chronic inducible urticaria who remain symptomatic despite treatment with H1 antihistamine.
The purpose of this Phase 3 study is to evaluate the safety and clinical efficacy of ligelizumab 240 mg and 120 mg given subcutaneously (s.c.) every 4 weeks (q4w) to ensure protection against allergic reaction by decreasing the sensitivity to oral…
The purpose of the study is to establish the efficacy and safety of ligelizumab in treating adult and adolescent subjects with chronic spontaneous urticaria. This study also looks how:• further treatment of ligelizumab works following ligelizumab or…
The primary objective is to determine the absorption of orally administered antibiotics in patients with SBS, to guide in clinical decision making when faced with catheter related infections.